Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Stockholders Equity (Deficit)

v3.21.1
Condensed Consolidated Statements of Stockholders Equity (Deficit) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Noncontrolling Interest [Member]
Series B Preferred Stock [Member]
Total
Balance at Dec. 31, 2019 $ 17,000 $ 232,580,000 $ (235,537,000) $ (2,878,000) $ 4,761,000 $ (1,057,000)
Balance (in shares) at Dec. 31, 2019 16,806,430       7,638  
Stock-based compensation $ 0 83,000 0 0 $ 0 83,000
Series A Preferred Stock Dividends 0 0 (62,000) 0 0 (62,000)
Issuance of SYN Biomics Stock $ 0 0 0 26,000 $ 0 26,000
Conversion of Series B Preferred Stock to Common (in shares) 933,045       (1,073)  
Conversion of Series B Preferred Stock to Common $ 1,000 1,072,000 (404,000) 0 $ (669,000) 0
Net loss 0 0 (2,964,000)   0 (2,964,000)
Non-controlling interest 0 0   (26,000) 0 (26,000)
Balance at Mar. 31, 2020 $ 18,000 233,735,000 (238,967,000) (2,878,000) $ 4,092,000 (4,000,000)
Balance (in shares) at Mar. 31, 2020 17,739,475       6,565  
Balance at Dec. 31, 2020 $ 29,000 240,821,000 (248,094,000) (2,773,000) $ 2,477,000 (7,540,000)
Balance (in shares) at Dec. 31, 2020 29,249,925       3,973  
Stock-based compensation $ 0 101,000 0 0 $ 0 101,000
Stock issued under "at-the-market" offering $ 79,000 65,881,000 0 0 0 65,960,000
Stock issued under "at-the-market" offering (in shares) 78,685,315          
Warrants Exercised $ 12,000 8,030,000 0 0 0 8,042,000
Warrants Exercised (In shares) 11,655,747          
Series A Preferred Stock Dividends $ 0 0 (24,000)   0 (24,000)
Effect of Series A Preferred Stock price adjustment $ 0 7,402,000 (7,402,000) 0 $ 0 0
Conversion of Series B Preferred Stock to Common (in shares) 3,454,783       (3,973)  
Conversion of Series B Preferred Stock to Common $ 3,000 3,971,000 (1,497,000) 0 $ (2,477,000) 0
Conversion of Series A Preferred Stock to Common $ 9,000 12,813,000 0 0 0 12,822,000
Conversion of Series A Preferred Stock to Common (in shares) 8,996,768          
Net loss $ 0 0 (2,536,000)   0 (2,536,000)
Non-controlling interest 0 0   (1,000) 0 (1,000)
Balance at Mar. 31, 2021 $ 132,000 $ 339,019,000 $ (259,553,000) $ (2,774,000) $ 0 $ 76,824,000
Balance (in shares) at Mar. 31, 2021 132,042,538